HSR25-160: Evaluating Patient Characteristics, Treatment Patterns, Clinical Outcomes, and Health Care Resource Use in Pemigatinib-Treated Cholangiocarcinoma (CCA) Patients: A Focus on Cancer of Unknown Primary
"HSR25-160: Evaluating Patient Characteristics, Treatment Patterns, Clinical Outcomes, and Health Care Resource Use in Pemigatinib-Treated Cholangiocarcinoma (CCA) Patients: A Focus on Cancer of Unknown Primary" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Authors
- Nicole Engel-Nitz
- Shreekant Parasuraman (ORCID: https://orcid.org/0000-0001-8162-8171)
- Sumit Verma (ORCID: https://orcid.org/0000-0003-1992-4556)
- Sunyoung Lee (ORCID: https://orcid.org/0000-0002-6893-3136)
- Alejandro Hughes (ORCID: https://orcid.org/0000-0002-4608-4217)
- Mike Blecker
- Milind Javle
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Optum (United States) (US)
- Incyte (United States) (US)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2025-03-28
- DOI
- https://doi.org/10.6004/jnccn.2024.7261
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00